{"id":"https://openalex.org/W3036617848","doi":null,"title":"Respiratory 2020: Oral Poziotinib shows clinical activity and durable response in previously treated EGFR exon 20 NSCLC patients \u2013a phase 2 study- Mark A Socinski, Spectrum Pharmaceuticals Inc.","display_name":"Respiratory 2020: Oral Poziotinib shows clinical activity and durable response in previously treated EGFR exon 20 NSCLC patients \u2013a phase 2 study- Mark A Socinski, Spectrum Pharmaceuticals Inc.","publication_year":2020,"publication_date":"2020-01-01","ids":{"openalex":"https://openalex.org/W3036617848","mag":"3036617848"},"language":"en","primary_location":{"id":"mag:3036617848","doi":null,"is_oa":false,"landing_page_url":"https://www.alliedacademies.org/articles/respiratory-2020-oral-poziotinib-shows-clinical-activity-and-durable-response-in-previously-treated-egfr-exon-20-nsclc-p.pdf","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null},"volume":null,"type":"article","indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5078629724","display_name":"Mark A. Socinski","orcid":"https://orcid.org/0000-0003-2915-9325","observed_orcids":["https://orcid.org/0000-0003-2915-9325","https://orcid.org/0000-0002-8213-0137"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Mark A. Socinski","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-2915-9325","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5078629724"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.10455321,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"4","issue":"1","first_page":"1","last_page":"2"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/poziotinib","display_name":"poziotinib","score":0.968999981880188},{"id":"https://openalex.org/keywords/egfr-exon-20-insertion-mutation","display_name":"EGFR exon 20 insertion","score":0.8059999942779541},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9909999966621399},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.7870000004768372},{"id":"https://openalex.org/keywords/oral-targeted-therapy","display_name":"oral targeted therapy","score":0.6179999709129333},{"id":"https://openalex.org/keywords/previously-treated-patients","display_name":"previously treated patients","score":0.8029999732971191},{"id":"https://openalex.org/keywords/disease-control-rate","display_name":"disease control rate","score":0.9010000228881836},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.734000027179718},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7710000276565552},{"id":"https://openalex.org/keywords/dose-reduction","display_name":"dose reduction","score":0.5609999895095825},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.6859999895095825},{"id":"https://openalex.org/keywords/treatment-adherence","display_name":"medication adherence","score":0.3619999885559082}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6315265893936157},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.6284196376800537},{"id":"https://openalex.org/C36823959","wikidata":"https://www.wikidata.org/wiki/Q373027","display_name":"Exon","level":3,"score":0.5727682709693909},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5185973644256592},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4982156753540039},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4172824025154114},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.330258309841156},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.3195847272872925},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.16684845089912415},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.14436310529708862},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:3036617848","doi":null,"is_oa":false,"landing_page_url":"https://www.alliedacademies.org/articles/respiratory-2020-oral-poziotinib-shows-clinical-activity-and-durable-response-in-previously-treated-egfr-exon-20-nsclc-p.pdf","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3082739148","https://openalex.org/W3154173462","https://openalex.org/W3031575375","https://openalex.org/W3182276024","https://openalex.org/W3138654081","https://openalex.org/W2898137622","https://openalex.org/W3134581027","https://openalex.org/W2767428437","https://openalex.org/W4285745229","https://openalex.org/W4387825292"],"abstract_inverted_index":{"The":[0],"board":[1],"of":[2,27,48,62,132,152,157,170,196,234,237,279,325,333,349,380,473,499,587,604,621,628,635,671,713,718,733,746,760],"non-little":[3,611],"cell":[4,612],"lung":[5,613,623],"malignant":[6,591],"growth":[7,592],"(NSCLC)":[8,615],"with":[9,55,67,149,199,204,228,241,270,315,362,506,556,584,610,686],"EGFR":[10,31,68,734,738],"exon":[11,34,69],"20":[12,35,70],"transformations":[13,72],"is":[14,20,593],"a":[15,41,77,150,651],"neglected":[16],"clinical":[17,226,534],"need.":[18],"Poziotinib":[19,63,84,223],"an":[21,378,427],"intense":[22],"irreversible":[23],"tyrosine":[24,701],"kinase":[25,695,702,709],"inhibitor":[26],"wild":[28],"kind":[29],"and":[30,32,56,60,139,159,193,256,260,275,285,302,318,331,346,357,396,411,422,439,463,471,488,539,542,559,571,600,643,660,716,742],"HER2":[33],"inclusion":[36,71],"freaks.":[37],"Understanding":[38],"pharmacokinetics":[39],"exhibited":[40],"portion":[42,205,255],"relative":[43],"increment":[44],"in":[45,64,76,120,231,264,426,522,548,551,581,676,763],"plasma":[46],"(half-existence":[47],"7.9":[49],"hr":[50],"at":[51],"16":[52,85],"mg":[53,86,209],"QD)":[54],"no":[57],"gathering.":[58],"Adequacy":[59],"security":[61,330],"NSCLC":[65,636,672],"patients":[66,144,685],"(ZENITH20-1)":[73],"was":[74,103,114,190,214],"concentrated":[75],"multi-focus":[78],"stage":[79],"2":[80],"examination.":[81],"Patients":[82],"got":[83],"QD":[87],"(portion":[88],"decreases":[89],"allowed":[90],"for":[91,98,258,369,520,533,684],"AEs)":[92],"until":[93],"movement,":[94],"or":[95,367,371,374,404,430,452,486],"terrible":[96],"AE":[97],"24":[99],"mo.":[100,183,187],"essential":[101],"endpoint":[102],"target":[104],"reaction":[105,133],"rate":[106,129],"(ORR),":[107],"RECIST":[108],"v1.":[109],"(Focal":[110],"radiographic":[111],"read).":[112],"ORR":[113,179,213],"accomplished":[115,683],"if":[116],"the":[117,121,197,276,298,323,329,363,391,406,420,434,459,469,479,518,552,557,578,585,594,601,608,626,629,668,714,730,743,757],"95%":[118],"CI>17%":[119],"ITT":[122],"Population.":[123],"Auxiliary":[124],"endpoints":[125],"were":[126,161],"malady":[127],"control":[128,541],"(DCR),":[130],"term":[131],"(DOR),":[134],"movement":[135,677],"free":[136,678],"endurance":[137,679],"(PFS)":[138,680],"security.":[140],"One":[141],"hundred":[142],"fifteen":[143],"middle":[145,151],"age":[146],"61":[147],"years":[148],"two":[153],"earlier":[154],"treatments":[155,662,719],"comprising":[156],"chemo":[158],"immunotherapy":[160],"examined.":[162],"Results":[163],"show":[164],"65%":[165],"had":[166],"tumor":[167,229],"decrease;":[168],"DCR":[169],"69%;":[171],"PR":[172],"15%":[173],"affirmed":[174],"4%":[175],"unsubstantiated;":[176],"54%":[177],"SD;":[178],"15%;":[180],"DOR":[181],"7.4":[182],"furthermore,":[184],"PFS":[185],"4.2":[186],"wellbeing":[188],"profile":[189],"system":[191],"related":[192],"like":[194],"others":[195],"class":[198],"understanding":[200],"consistence":[201],"improvement":[202,745],"saw":[203],"decrease":[206,230],"to":[207,246,253,272,311,484,565,576,736,750],"12":[208],"QD.":[210],"In":[211,625],"outline,":[212],"lower":[215],"than":[216,456],"anticipated;":[217],"be":[218,447],"that":[219,282,287,313,360,375,384,393,408,436,461,481,545,720],"as":[220,588],"it":[221],"may,":[222],"showed":[224],"unequivocal":[225],"action":[227],"dominant":[232],"part":[233],"patients.":[235],"Effect":[236],"medication":[238,327,335,398,413,441,492],"consistence/occasions":[239],"combined":[240],"its":[242,319,372],"short":[243],"half-life":[244],"due":[245],"AEs":[247],"may":[248,400,415,445,467,494],"have":[249,681,755],"diminished":[250],"viability.":[251],"Studies":[252],"streamline":[254],"calendar":[257],"continuous":[259],"future":[261,273,277],"investigations":[262],"are":[263,308,376,546],"progress.\u00a0\r\nThis":[265],"introduction":[266,583],"contains":[267],"forward-looking":[268],"proclamations":[269,570],"respect":[271],"occasions":[274],"execution":[278],"Spectrum":[280,370],"Pharmaceuticals":[281],"include":[283],"dangers":[284,544],"vulnerabilities":[286],"could":[288,385],"make":[289,386,468],"real":[290,387],"outcomes":[291,388],"contrast":[292,389],"tangibly.":[293],"These":[294,304],"announcements":[295,305],"depend":[296],"on":[297,531,723],"executives'":[299],"present":[300],"convictions":[301],"desires.":[303],"incorporate":[306,390],"however":[307],"not":[309,377,401,416,446,476],"constrained":[310,512],"articulations":[312],"identify":[314,361],"our":[316,321,326,334,394,409,437,474,482,497,503,511,515,529,633],"business":[317,526],"future,":[320],"technique,":[322],"accomplishment":[324],"competitors,":[328],"viability":[332,715],"items,":[336],"item":[337,341,351,353],"endorsements,":[338],"showcase":[339],"potential,":[340],"deals,":[342],"income,":[343],"advancement,":[344],"administrative":[345,424],"endorsement":[347,418],"courses":[348],"events,":[350],"dispatches,":[352],"acquisitions,":[354],"capital":[355],"assets":[356],"any":[358,432,567,574],"explanations":[359],"purpose,":[364],"conviction,":[365],"plans":[366],"desires":[368],"administration,":[373],"announcement":[379],"authentic":[381],"certainty.":[382],"Dangers":[383],"likelihood":[392,407,435,460,480],"current":[395,410,438],"new":[397,412,440],"competitors":[399],"demonstrate":[402],"sheltered":[403],"powerful,":[405],"applicants":[414],"get":[417],"from":[419],"FDA":[421],"other":[423,464],"offices":[425],"opportune":[428],"way":[429],"by":[431,617,656,664],"means,":[433],"up-and-comers,":[442],"whenever":[443],"affirmed,":[444],"increasingly":[448],"successful,":[449],"more":[450,453],"secure":[451],"cost":[454,462],"proficient":[455],"contending":[457],"drugs,":[458],"serious":[465],"weights":[466],"promoting":[470],"offer":[472],"medications":[475],"financially":[477],"achievable,":[478],"endeavors":[483],"gain":[485],"in-permit":[487],"build":[489],"up":[490,508],"extra":[491],"up-and-comers":[493],"fall":[495],"flat,":[496],"absence":[498],"continued":[500],"income":[501],"history,":[502],"restricted":[504],"involvement":[505],"setting":[507],"key":[509],"unions,":[510],"showcasing":[513],"experience,":[514],"client":[516,523],"focus,":[517],"opportunities":[519],"changes":[521,659,711],"orders,":[524],"developing":[525],"sector":[527],"elements,":[528],"reliance":[530],"outsiders":[532],"preliminaries,":[535],"fabricating,":[536],"dispersion,":[537],"data":[538,579],"quality":[540],"different":[543],"depicted":[547],"further":[549],"detail":[550],"Company's":[553],"reports":[554],"recorded":[555],"Securities":[558],"Exchange":[560],"Commission.":[561],"We":[562],"don't":[563],"plan":[564],"refresh":[566,577],"such":[568],"forwardlooking":[569],"explicitly":[572,721],"disavow":[573],"obligation":[575],"contained":[580],"this":[582],"exception":[586],"legally":[589],"necessary.\u00a0\r\nLung":[590],"most":[595,619,630],"widely":[596],"recognized":[597],"harmful":[598],"infection":[599],"main":[602],"source":[603],"disease":[605],"mortality":[606],"around":[607],"world,":[609],"malignancy":[614],"containing":[616],"far":[618],"(85%)":[620],"all":[622],"malignancies.":[624],"course":[627],"recent":[631],"decade,":[632],"comprehension":[634],"has":[637],"developed":[638],"past":[639],"expansive":[640],"histological":[641],"subtypes":[642],"'one":[644],"size":[645],"fits":[646],"all'":[647],"treatment":[648,762],"approaches":[649],"toward":[650],"refined":[652],"illness":[653],"arrangement":[654],"supported":[655],"characterized":[657],"hereditary":[658],"accuracy":[661],"guided":[663],"atomic":[665],"delineation.":[666],"For":[667],"adenocarcinoma":[669,741],"subtype":[670],"specifically,":[673],"huge":[674],"upgrades":[675],"been":[682],"epidermal":[687],"development":[688],"factor":[689],"receptor":[690,700],"(EGFR)":[691],"transformations,":[692],"anaplastic":[693],"lymphoma":[694],"(ALK)":[696],"translocations,":[697],"ROS1":[698],"proto-oncogene":[699],"(ROS1)":[703],"adjustments":[704],"and,":[705],"B-raf":[706],"proto-oncogene,":[707],"serine/threonine":[708],"(BRAF)":[710],"because":[712],"accessibility":[717],"focus":[722],"these":[724,728],"sub-atomic":[725],"drivers.":[726],"Among":[727],"advances,":[729],"fruitful":[731],"utilization":[732],"inhibitors":[735,749],"treat":[737],"freak":[739],"positive":[740],"ensuing":[744],"third":[747],"era":[748],"handle":[751],"procured":[752],"sedate":[753],"obstruction":[754],"become":[756],"perfect":[758],"example":[759],"focused":[761],"oncology.":[764]},"counts_by_year":[],"updated_date":"2026-09-26T08:19:03.415552","created_date":"2020-06-25T00:00:00"}